Savara Announces Participation in Jefferies Global Healthcare Conference
The live webcast and subsequent replay will be available on the 'Events & Presentations' section of the Company's corporate website and will be archived for 90 days.
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is delivered via an investigational eFlow ® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of a large molecule. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com and LinkedIn.
*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. It is not approved in any indication. MOLBREEVI is a trademark of Savara Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Texas Instruments Stock Nosedives After Shock Earnings Outlook
July 23 - Texas Instruments (NASDAQ:TXN) shares fell more than 10% in pre-market trading Wednesday after its third-quarter revenue outlook came in below Wall Street estimates, despite delivering stronger-than-expected results for the second quarter. Warning! GuruFocus has detected 11 Warning Signs with TXN. The chipmaker reported Q2 revenue of $4.45 billion, topping the $4.36 billion analyst consensus, and earnings per share of $1.41, also ahead of the expected $1.35. Net income rose 15% year over year to $1.3 billion. Analog chip revenue, the company's core segment, climbed 18% to $3.5 billion, exceeding projections. The growth was driven by demand from the automotive and industrial markets. However, Texas Instruments guided Q3 revenue in the range of $4.45 billion to $4.8 billion, with a midpoint slightly below the $4.59 billion consensus. The company also forecast EPS between $1.36 and $1.60, bracketing analysts' $1.50 average. Shares had been up 15% year to date before the report, helped by broader enthusiasm in the semiconductor sector. The company recently committed $60 billion toward U.S. chip factory expansion, a plan supported by the Trump administration's domestic tech push. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 minutes ago
- Yahoo
Rezolve AI PLC (RZLV) To Support Stablecoin Transactions
Rezolve AI (NASDAQ:RZLV) is one of the top AI stocks with tremendous upside potential. On July 21, the company confirmed that its platform is well-positioned to support stablecoin transactions following the passing of the GENIUS Act. The passing of the GENIUS Act is welcome, as Rezolve AI has carved a niche in offering artificial intelligence-powered solutions that enhance customer engagement while optimizing revenue. Its platform delivers tools that utilize AI to improve the digital experience and decision-making processes. 'The GENIUS Act is expected to transform stablecoins from speculative assets into regulated digital dollars,' said Daniel M. Wagner, CEO of Rezolve AI. 'Tether's commitment to compliance is a milestone, and Rezolve believes it is ready to connect this new liquidity to the real economy.' The Rezolve AI Brain Suite platform is already integrated into Microsoft Azure and Google Cloud infrastructure to support wallet-based payments. The Microsoft and Google integrations enable enterprise-grade scalability and deployment, therefore exposing the company to a $30 trillion market globally. Rezolve AI (NASDAQ:RZLV) is a pure-play artificial intelligence (AI) company that develops proprietary Large Language Models (LLMs) tailored for the retail sector. Its Brain Suite of AI solutions helps retailers deepen customer engagement, streamline operations, and boost sales with scalable AI-driven tools. While we acknowledge the potential of RZLV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Chemical Stocks to Buy According to Billionaires and 7 Most Undervalued Pot Stocks To Buy According To Analysts. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
15 minutes ago
- Yahoo
Tesla Is Still Selling Glossy Future - GM Just Shipped 111% More EVs
Even with shares down 12% this year, Tesla Inc. (NASDAQ:TSLA) still carries an out-of-this-world price-to-earnings ratio of 189x. That's not just lofty—it's meme-level. Tesla's Valuation Is Still From Another Planet For context, Microsoft Corp (NASDAQ:MSFT) and Inc (NASDAQ:AMZN) sit around 39x and 37x (per Benzinga Pro data), while Toyota Motor Corp (NYSE:TM) and General Motors Co (NYSE:GM) trade at just 7 times earnings. Somehow, Tesla is still priced like it's leading a future that hasn't quite arrived. That future was easier to believe in back in 2020, when Tesla shares soared nearly 700% and the company truly dominated the EV narrative. But the landscape has shifted – and fast. Read Also: Competition Isn't Creeping—It's Sprinting On Tuesday, GM reported that its electric vehicle sales surged 111% year-over-year in the second quarter. Sure, it's off a smaller base, but the trajectory is undeniable. Meanwhile, Tesla's own second-quarter vehicle sales fell 14%. In a market that once gave Tesla credit for being the only EV in town, that's a glaring reversal. GM isn't the only challenger. Chinese automakers are rapidly scaling up production and expanding their global reach, offering more affordable alternatives with comparable technology. Tesla no longer feels like a monopoly. It feels like a frontrunner being caught from all sides. Can Hype Still Outrun The Numbers? Elon Musk is still Elon Musk—and few CEOs can spin a narrative quite like him. He's teased robotaxis, humanoid robots, and full autonomy as Tesla's next growth engine. But with each sales miss, the pressure mounts to deliver something—anything—that justifies the valuation. Tesla's earnings call on Wednesday may offer another round of ambitious promises. But this time, with competitors closing in and fundamentals weakening, even the meme premium may need a reality check. For now, Tesla is still trading like it's 2020. The rest of the EV world, however, is firmly in 2025. TSLA Price Action: Tesla shares were up 0.31% at $333.13 on Wednesday, according to Benzinga Pro. Read Next: Photo: Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? TESLA (TSLA): Free Stock Analysis Report GENERAL MOTORS (GM): Free Stock Analysis Report This article Tesla Is Still Selling Glossy Future - GM Just Shipped 111% More EVs originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
